Background: Standard chemotherapy for patients with metastatic colorectal cancer (mCRC) or gastric cancer (GC) consists of two-drug, usually fluoropyrimidine-based, combinations, with or without the addition of biological agents. Studies of triple-drug regimens combining 5-fluorouracil (5-FU)/folinic acid (FA) with both oxaliplatin and irinotecan have shown promising efficacy in studies of patients with mCRC or GC. However, improved efficacy has often been achieved at the expense of high rates of grade 3 or 4 toxicities such as neutropenia and diarrhoea, occasionally even resulting in toxic deaths.
Objective/Methods: We performed a phase II study of previously untreated patients with mCRC or GC to assess the safety and efficacy of our 5-fluorouracil/folinic acid/oxaliplatin/irinotecan (FUFOXIRI) regimen with weekly administration of irinotecan 70 mg/m 2, oxaliplatin 50 mg/m2, FA 500 mg/m2 and 5-FU 2000 mg/m2 on days 1, 8, 15 and 22, repeated from day 36.
Results: A total of 22 patients were enrolled, 11 each with mCRC and GC receiving a median of four cycles per patient. The FUFOXIRI regimen was generally well tolerated with no toxic deaths, neutropenic fever or grade 4 toxicities. Most common grade 3 side effects were diarrhoea and neutropenia each affecting 24% of patients. Dose reductions due to toxicity were performed in 48% of all and 60% of patients having received at least two cycles of FUFOXIRI. The overall response rate was 46% (all partial responses), 55% and 36% for patients with mCRC and GC, respectively. Median progression-free survival for all patients, mCRC and GC patients was 9.5, 10.0 and 8.0 months, respectively. The median overall survival for all patients was 16.5, 18.0 and 15.0 months for patients with mCRC and GC, respectively.
Conclusion: These data show excellent tolerance and efficacy of the FUFOXIRI regimen in both mCRC and GC. Therefore, FUFOXIRI is a promising backbone for future studies incorporating biologic ‘targeted’ agents for the treatment of gastrointestinal cancers.
Abad, A.A., Massuti, B.B., Gallego, J.C., Yuste, A.L.B., Manzano, J.L.A., Carrato, A.C. et al. (2004) Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. Anti-Cancer Drug15: 469-471.
2.
Ajani, J.A., Fodor, M.B., Tjulandin, S.A., Moiseyenko, V.M., Chao, Y., Filho, S.C. et al. (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol23: 5660-5667.
3.
Ajani, J.A., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C. et al. (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group . J Clin Oncol25: 3205-3209.
4.
Al-Batran, S.-E., Atmaca, A., Hegewisch-Becker, S., Jaeger, D., Hahnfeld, S., Rummel, M.J. et al. (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol22: 658-663.
5.
Al-Batran, S.-E., Hartmann, J.T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R. et al. (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol26: 1435-1442.
6.
Aparicio, J., Fernandez-Martos, C., Vincent, J.M., Maestu, I., Llorca, C., Busquier, I. et al. (2005) FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer5: 263-267.
7.
Arnold, D., Hohler, T., Dittrich, C., Lordick, F., Seufferlein, T., Riemann, J. et al. (2008) Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol19: 1442-1449.
8.
Bismuth, H., Adam, R., Levi, F., Farabos, C., Waechter, F., Castaing, D. et al. (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg224: 509-522.
9.
Blanke, C.D., Haller, D.G., Benson, A.B., Rothenberg, M.L., Berlin, J., Mori, M. et al. (2001) A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma . Ann Oncol12: 1575-1580.
10.
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., De Braud, F. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol27: 663-671.
11.
Bouche, O., Raoul, J.L., Bonnetain, F., Giovannini, M., Etienne, P.L., Lledo, G. et al. (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (Lv5fu2), Lv5fu2 plus cisplatin, or Lv5fu2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone De Cancerologie Digestive Group Study-Ffcd 9803. J Clin Oncol22: 4319-4328.
12.
Buechele, T., Schoeber, C., Kroening, H., Eckart, M., Lingenfelser, T., Respondek, M. et al. (1998) Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-Fu/ FA in patients (Pts) with advanced colorectal cancer (CRC): a preliminary report. Proc Am Soc Clin Oncol: Abstract 1106.
13.
Cals, L., Rixe, O., Francois, E., Favre, R., Merad, L., Deplanque, G. et al. (2004) Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol15: 1018-1024.
14.
Calvo, E., Cortes, J., Rodríguez, J., Fernández-Hidalgo, O., Rebollo, J., Martín-Algarra, S. et al. (2002) Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study . Clin Colorectal Cancer2: 104-110.
15.
Cao, W., Yang, W., Lou, G., Jiang, J., Geng, M., Xi, W. et al. (2009) Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer . Anticancer Drugs20: 287-293.
16.
Chao, Y., Yeh, K.H., Chang, C.J., Chen, L.T., Chao, T.Y., Wu, M.F. et al. (2004) Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer91: 453-458.
17.
Chiesa, M.D., Buti, S., Tomasello, G., Negri, F., Buononato, M. and Brunelli, A. ( 2007) A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. Tumori93: 244-247.
18.
Comella, P., Lorusso, V., Maiorino, L., Casaretti, R., Cannone, M., Massidda, B. et al. (2009) Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol64: 893-899.
19.
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van De Velde, C.J.H., Nicolson, M. et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med355: 11-20.
20.
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F. et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med358: 36-46.
21.
Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C. et al. (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol19: 1450-1457.
22.
De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J. et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol18: 2938-2947.
23.
De La Cámara, J., Rodriguez, J., Rotellar, F., Viudez, A., García-Foncillas, J., Pardo, F. et al. (2004) Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol22: Abstract 3593.
24.
De Vita, F., Orditura, M., Matano, E., Bianco, R., Carlomagno, C., Infusino, S. et al. (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer92: 1644-1649.
25.
Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P. et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355: 1041-1047.
26.
Falcone, A., Masi, G., Allegrini, G., Danesi, R., Pfanner, E., Brunetti, I.M. et al. (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol20: 4006-4014.
27.
Falcone, A.M., Orlandini, C., Barbara, C., Benedetti, G., Evangelista, W., Picone, V. et al. (2007a) Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): subgroup and multivariate analysis. ASCO 2007 Gastrointestinal Cancers Symposium: Abstract 287.
28.
Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C. et al. (2007b) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol25: 1670-1676.
29.
Falcone, A., Masi, G., Loupakis, F., Vasile, E., Ciarlo, A., Cavaciocchi, D., Amoroso, D. et al. (2008) FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (Bv) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O Group . J Clin Oncol26(suppl): Abstract 4031.
30.
Ferrari, V., Valcamonico, F., Amoroso, V., Simoncini, E., Vassalli, L., Marpicati, P. et al. (2005) An alternating regimen of irinotecan/5-fluorouracil/ folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: a phase II trial. Oncology69: 283-289.
31.
Fischel, J.L., Rostagno, P., Formento, P., Dubreuil, A., Etienne, M.C. and Milano, G. ( 2001) Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer84: 579-585.
32.
Folprecht, G., Grothey, A., Alberts, S., Raab, H.R. and Kohne, C.H. ( 2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol16: 1311-1319.
33.
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C. et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol18: 136-147.
34.
Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K. et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol22: 23-30.
35.
Grothey, A., Deschler, B., Kroening, H., Ridwelski, K., Reichardt, P., Kretschmar, A. et al. (2001) Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (Oxa) in advanced colorectal cancer (CRC). Results of a phase III study. Proc Am Soc Clin Oncol20: Abstract 496.
36.
Grothey, A., Deschler, B., Kroening, H., Ridwelski, K., Reichardt, P., Kretzschmar, A. et al. (2002) Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (Oxa) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol21: Abstract 512.
37.
Grothey, A., Sargent, D., Goldberg, R.M. and Schmoll, H.-J. ( 2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol22: 1209-1214.
38.
Gruenberger, T., Kaczirek, K., Bergmann, M., Zielinski, C.C. and Gruenberger, B. ( 2008) Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. J Clin Oncol26(suppl): Abstract 4073.
39.
Hochster, H.S., Hart, L.L., Ramanathan, R.K., Childs, B.H., Hainsworth, J.D., Cohn, A.L. et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the Tree Study. J Clin Oncol26: 3523-3529.
40.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
41.
Hurwitz, H.I., Fehrenbacher, L., Hainsworth, J.D., Heim, W., Berlin, J., Holmgren, E. et al. (2005) bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer . J Clin Oncol23: 3502-3508.
42.
Kohne, C.H., Van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M.P. et al. (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol23: 4856-4865.
43.
Lee, J., Kang, W.K., Kwon, J.M., Oh, S.Y., Lee, H.R., Kim, H.J. et al. (2007) Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol18: 88-92.
44.
Lordick, F., Lorenzen, S., Stollfuss, J., Vehling-Kaiser, U., Kullmann, F., Hentrich, M. et al. (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer93: 190-194.
45.
Louvet, C., Andre, T., Tigaud, J.M., Gamelin, E., Douillard, J.Y., Brunet, R. et al. (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients . J Clin Oncol20: 4543-4548.
46.
Lutz, M.P., Wilke, H., Wagener, D.J.T., Vanhoefer, U., Jeziorski, K., Hegewisch-Becker, S. et al. (2007) Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol25: 2580-2585.
47.
Masi, G., Allegrini, G., Cupini, S., Marcucci, L., Cerri, E., Brunetti, I. et al. (2004) First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a Phase II study with a simplified biweekly schedule. Ann Oncol15: 1766-1772.
48.
Masi, G., Vasile, E., Loupakis, F., Bursi, S., Ricci, S., Petrini, I. et al. (2008) Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer . Clin Colorectal Cancer7: 7-14.
49.
McWilliams, R.R., Goetz, M.P., Morlan, B.W., Salim, M., Rowland, K.M., Krook, J.E. et al. (2007) Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/ leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer6: 516-521.
50.
Moehler, M., Hoffmann, T., Hildner, K., Siebler, J., Galle, P.R. and Heike, M. ( 2002) Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol40: 957-964.
51.
Moehler, M., Eimermacher, A., Siebler, J., Hohler, T., Wein, A., Menges, M. et al. (2005) Randomised phase ii evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (Ilf) vs 5-fluorouracil, leucovorin, and etoposide (Elf) in untreated metastatic gastric cancer. Br J Cancer92: 2122-2128.
52.
Patel, M., Agarwal, R. and Ardalan, B. ( 2004) Effects of oxaliplatin and Cpt-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines. J Cancer Res Clin Oncol130: 453-459.
53.
Peinert, S., Grothe, W., Kuehne, I., Kegel, T., Arnold, D. and Schmoll, H.J. ( 2006) BECAM: a salvage protocol with bevacizumab, capecitabin, and mitomycin C for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab. Ann Oncol 17(Suppl 1): Abstract PO-34.
54.
Pozzo, C., Barone, C., Szanto, J., Padi, E., Peschel, C., Bukki, J. et al. (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol15: 1773-1781.
55.
Reina, J.J., Sanchez-Rovira, P., Bernabé, R., Bolaños, M., González, E., Belón, J. et al. (2004) Biweekly administration of irinotecan (CPT-11), oxaliplatin (Ox) and 5-fluorouracil (5-FU) as first-line treatment of advanced or metastatic colorectal cancer (MCRC). ASCO Ann Meet Proceed22: Abstract 3561.
56.
Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J. et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med343: 905-914.
57.
Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol26: 2013-2019.
58.
Sanoff, H.K., Sargent, D.J., Campbell, M.E., Morton, R.F., Fuchs, C.S., Ramanathan, R.K. et al. (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol26: 5721-5727.
59.
Santomaggio, A., Ricevuto, E., Cannita, K., Bruera, G., Tudini, M., Lanfiuti Baldi, P. et al. (2009) ‘‘Poker’’ schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/ FOX) in advanced colorectal cancer: a phase II study. J Clin Oncol27: Abstract 4125.
60.
Sargent, D.J., Kohne, C.H., Sanoff, H.K., Bot, B.M., Seymour, M.T., De Gramont, A. et al. (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol27: 1948-1955.
61.
Sastre, J., Garcia-Saenz, J.A. and Diaz-Rubio, E. ( 2006) Chemotherapy for gastric cancer. World J Gastroenterol12: 204-213.
62.
Seium, Y., Stupp, R., Ruhstaller, T., Gervaz, P., Mentha, G., Philippe, M. et al. (2005) Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol16: 762-766.
63.
Souglakos, J., Mavroudis, D., Kakolyris, S., Kourousis, C., Vardakis, N., Androulakis, N. et al. (2002) Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol20: 2651-2657.
64.
Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A. et al. (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) . Br J Cancer94: 798-805.
65.
Tabernero, J., Van Cutsem, E., Diaz-Rubio, E., Cervantes, A., Humblet, Y., Andre, T. et al. (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol25: 5225-5232.
66.
Tanaka, R., Ariyama, H., Qin, B., Shibata, Y., Takii, Y., Kusaba, H. et al. (2005) Synergistic interaction between oxaliplatin and sn-38 in human gastric cancer cell lines in vitro. Oncol Rep14: 683-688.
67.
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst92: 205-216.
68.
Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M. et al. (2006) Optimox1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a Gercor study. J Clin Oncol24: 394-400.
69.
Vamvakas, L., Athanasiadis, A., Karampeazis, A., Kakolyris, S., Polyzos, A., Kouroussis, C. et al. (2009) Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol (Epub ahead of print).
70.
Van Cutsem, E., Kohne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A. et al. (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med360: 1408-1417.
71.
Van Cutsem, E., Kang, Y., Chung, H., Shen, L., Sawaki, A., Lordick, F. et al. (2009b) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (Her2)-positive advanced gastric cancer (GC). J Clin Oncol27: Abstract LBA4509.
72.
Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C. et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol24: 4991-4997.
73.
Vasile, E., Masi, G., Fornaro, L., Cupini, S., Loupakis, F., Bursi, S. et al. (2009) A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer100: 1720-1724.
74.
Wagner, A.D., Grothe, W., Haerting, J., Kleber, G., Grothey, A. and Fleig, W.E. ( 2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol24: 2903-2909.
75.
Wong, J.E.L., Ito, Y., Correa, P., Peeters, K.C.M.J., Van De Velde, C.J.H., Sasako, M. et al. (2003) Therapeutic strategies in gastric cancer. J Clin Oncol21: 267-269.
76.
Ychou, M., Viret, F., Kramar, A., Desseigne, F., Mitry, E., Guimbaud, R. et al. (2008) Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol62: 195-201.
77.
Yeh, K.H., Chen, A.L., Wan, J.P., Lin, C.S. and Liu, C.C. ( 2004) down-regulation of thymidylate synthase expression and its steady-state Mrna by oxaliplatin in colon cancer cells. Anticancer Drug15: 371-376.
